^
Association details:
| Biomarker: | NPM1 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | emilumenib succinate (DS-1594) (Menin-MLL inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1132 - Development and characterization of a novel orally bioavailable menin-MLL inhibitor for treatment of acute leukemia patients with MLL-rearrangement or NPM1 mutation
Published date:
03/10/2021
Excerpt:
DS-M1 demonstrates significant survival benefit...in patient-derived xenograft (PDX) models of MLL1-r or NPM1-mu acute leukemia. These data indicate that DS-M1 has a high potency as an antitumor drug with the potential to provide survival advantage in acute leukemia patients with MLL-r and NPM1-mu. MLL1-r pediatric B-ALL-PDX mice treated with 50 mg/kg bid for 28 days and NPM1-mu AML-PDX mice treated with 100 mg/kg bid for 35 days were all survived (ILS >254% and >300%) without any detectable leukemic blast cells in bone marrow at 120 and 60 days after cessation of therapy, respectively.
